AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca has launched a Phase 1 clinical study titled A Phase 1, Randomized, Single-blind, Placebo-controlled Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 in Combination With Ezetimibe, Ezetimibe/Rosuvastatin, or Ezetimibe/Bempedoic Acid in Healthy Male and Female Participants 18 to 75 Years of Age With Elevated LDL-C. The study aims to evaluate the pharmacokinetics, safety, tolerability, and efficacy of the drug AZD0780 when combined with ezetimibe, ezetimibe/rosuvastatin, or ezetimibe/bempedoic acid in individuals with elevated LDL cholesterol levels.
The intervention involves administering AZD0780, a new drug, alongside existing cholesterol-lowering medications like ezetimibe, rosuvastatin, and bempedoic acid. The goal is to assess the combined effects on LDL cholesterol levels.
This randomized, single-blind, placebo-controlled study uses a parallel intervention model. Participants are randomly assigned to receive either the drug combinations or a placebo, with the primary aim of treatment.
The study began on December 20, 2024, with an estimated completion date not yet specified. The latest update was submitted on August 1, 2025, indicating ongoing recruitment.
For investors, the study’s progress could influence AstraZeneca’s stock by showcasing potential advancements in cholesterol treatment. Positive results may boost investor confidence and position AstraZeneca favorably against competitors in the cardiovascular treatment market.
The study is currently recruiting, and further details can be accessed on the ClinicalTrials portal.